Concert is developing innovative medicines with unique therapeutic properties to address the needs of patients with chronic diseases.

CTP-692

A promising first-in-class approach to broaden the scope of treating schizophrenia

CTP-543

A drug candidate for alopecia areata, a disease with no currently-approved treatments

LATEST NEWS

Oct 12, 2019
Concert Pharmaceuticals Presents Positive Phase 2 Data in Alopecia Areata During Late-Breaker Session at EADV Congress

Oct 02, 2019
Concert Pharmaceuticals to Provide Overview of Clinical Pipeline at Cantor Healthcare Conference

© 2019 Concert Pharmaceuticals. All rights reserved.
HOME | SITEMAP | CONTACT | TERMS OF USE | PRIVACY POLICY
Back to Top